EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells

Qin Chen, Swanand Hardikar, Kimie Kondo, Nan Dai, Ivan R Corrêa iD, Meigen Yu, Marcos R Estecio, Xing Zhang, Taiping Chen, Xiaodong Cheng iD

NAR Cancer · 2025

DOI: 10.1093/narcan/zcaf018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Qin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: DNA (Cytosine-5-)-Methyltransferases, Lung Neoplasms, DNA (Cytosine-5-)-Methyltransferase 1, Pyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA methylation alterations, including hypermethylation and silencing of tumor suppressor genes, contribute to cancer formation and progression. The FDA-approved nucleoside analogs azacytidine and decitabine are effective demethylating agents for hematologic malignancies but their general use has been limited by their toxicity and ineffectiveness against solid tumors. GSK-3484862, a dicyanopyridine-containing, DNMT1-selective inhibitor and degrader, offers a promising lead for developing novel demethylating therapeutics. Here, we demonstrate that GSK-3484862 treatment upregulates DNMT3B expression in lung cancer cell lines (A549 and NCI-H1299). Disrupting DNMT3B in NCI-H1299 sensitizes these cells to GSK-3484862, enhancing its inhibitory effects on cell viability and growth. GSK-3484862 treatment induces demethylation at DNMT3B regulatory elements including a candidate enhancer located ∼10 kb upstream of the DNMT3B transcription start site, as well as at the promoter of TERT (telomerase reverse transcriptase), a potential activator of DNMT3B expression. These demethylation events correlate with upregulation of DNMT3B expression. These findings suggest that combining inhibitors targeting DNMT1, the maintenance methyltransferase, with those targeting DNMT3A/3B, the de novo methyltransferases, or using pan-DNMT inhibitors, could enhance anticancer efficacy and reduce resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA (Cytosine-5-)-MethyltransferasesLung NeoplasmsDNA (Cytosine-5-)-Methyltransferase 1PyridinesHumansDNA Methyltransferase 3BGene Expression Regulation, NeoplasticCell Line, TumorDNA MethylationCell ProliferationCell SurvivalA549 CellsPromoter Regions, GeneticUp-Regulation

Substanzen

DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanPyridines

Autor:innen und Institutionen

  • Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • New England Biolabs, Inc., Ipswich, MA 01938, United States.

ORCID-Profile: Ivan R Corrêa, Xiaodong Cheng

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NLM NIH HHS
  • National Institutes of Health
  • Cancer Prevention and Research Institute of Texas
  • National Library of Medicine Training Program in Biomedical Informatics and Data Science
  • Texas Tobacco Settlement–Molecular Mechanisms of Tobacco Carcinogenesis
  • CPRIT Scholars in Cancer Research

Zitieren

APA

Chen, Q., Hardikar, S., Kondo, K., Dai, N., Corrêa, I. R., Yu, M., Estecio, M. R., Zhang, X., Chen, T., & Cheng, X. (2025). GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells. NAR Cancer. https://doi.org/10.1093/narcan/zcaf018

Vancouver

Chen Q, Hardikar S, Kondo K, Dai N, Corrêa IR, Yu M, et al. GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells. NAR Cancer. 2025. doi:10.1093/narcan/zcaf018

BibTeX
@article{Chen2025,
  author = {Chen, Qin and Hardikar, Swanand and Kondo, Kimie and Dai, Nan and Corrêa, Ivan R and Yu, Meigen and Estecio, Marcos R and Zhang, Xing and Chen, Taiping and Cheng, Xiaodong},
  title = {GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells},
  journal = {NAR Cancer},
  year = {2025},
  doi = {10.1093/narcan/zcaf018}
}
Kostenlos starten →